HOME >> BIOLOGY >> NEWS
Avastin-Tarceva combo provides 'one-two' punch against lung cancer

Results of the first clinical trial to combine two new targeted cancer drugs suggest that the combination may provide a powerful "one-two punch" against lung cancer, the nation's leading cancer killer.

The work, led by researchers at the Vanderbilt-Ingram Cancer Center in Nashville, Tenn., and The University of Texas M.D. Anderson Cancer Center in Houston, was presented at the 40th annual meeting of the American Society of Clinical Oncology in New Orleans.

Tumors were controlled among 85 percent of the 40 patients with advanced non-small cell lung cancer (NSCLC) who entered the Phase I/II trial of a combined regimen of bevacizumab (Avastin TM) and erlotinib (Tarceva TM).

The response rate proportion of patients whose tumors shrank in size by more than half was about 20 percent, while median survival was 12.5 months. This compares to about 10 percent response and between six and eight months median survival with traditional therapy or erlotinib alone, said Alan Sandler, M.D., associate professor of Medicine and director of the lung cancer clinical program at Vanderbilt-Ingram.

The treatment resulted in only mild side effects, including rash and diarrhea, and the drugs did not appear to interact adversely with one another, the investigators report.

"The anti-tumor activity was encouraging," said Sandler, who presented the research at the meeting. "These findings suggest not only that combining these two agents is feasible, but that this approach may provide a one-two punch against tumors that should be further examined in larger clinical trials."

Lung cancer is the leading cause of cancer death in the United States, killing more than 157,000 people each year, more than the next four leading cancers (colorectal, breast, prostate and pancreas) combined. About 85 percent of all lung cancers are non-small cell cancers, and nearly half of these patients are diagnosed with advanced disease and receive only chemotherapy or supportive care,
'"/>

Contact: Cynthia Floyd Manley
cynthia.manley@vanderbilt.edu
615-430-8320
Vanderbilt University Medical Center
5-Jun-2004


Page: 1 2 3

Related biology news :

1. Drug combo effective in advanced breast cancer
2. Toxin combo common in fish appears capable of impairing motor skills
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. Rum and coke combo far worse on the brain, study shows
5. Study by Israeli scientists provides insight on DNA code
6. Study by Tufts biologist provides window into progression of some degenerative diseases
7. Rolling Store provides model for overcoming barriers to healthy foods and better health outcomes
8. Common worm provides insights into salmonella virulence
9. Motion that powers sperm provides key to unravelling rare genetic disorder
10. Chemical reaction in birds provides sense of direction during migratory flights
11. Engineered virus provides impetus in search for HIV vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2018)... (PRWEB) , ... August 29, ... ... study validates first non-invasive technology to identify specific chromosomal abnormalities using morphological ... Ovation Fertility and Australia-based Life Whisperer suggests that ...
(Date:8/26/2018)... ... August 24, 2018 , ... ... laboratories. However, this technology introduces many well-described challenges around data processing, storage ... South London NHS Genomic Medicine Centre. The Viapath Genetics Laboratories have implemented ...
(Date:8/23/2018)... ... ... Mandy is an eight-year-old mini Australian shepherd and a tripod. When Mandy was four years ... surgeries to try to repair the leg and each time it was unsuccessful. Once ... along with her veterinarian, decided to amputate. With only one front leg, mobility in ...
Breaking Biology News(10 mins):
(Date:9/13/2018)... ... ... Asymmetrex’s director, James L. Sherley, M.D., Ph.D., asks audiences questions like, “How ... the means to measure the number of drug molecules in drug development research or ... holding up progress in stem cell medicine.” , “Can you imagine taking an approved ...
(Date:9/12/2018)... ... September 12, 2018 , ... NDA Partners Chairman Carl ... Senior Director of Regulatory Affairs and Quality Systems at WellDoc, Inc., has joined ... Affairs and Quality Systems at WellDoc, Inc., she conducted quality control and supplier ...
(Date:9/7/2018)... ... September 06, 2018 , ... ... disease, has been validated to be as effective as manual pathology. The study, ... in Frozen Muscle Biopsies,” was published in the Archives of Pathology & Laboratory ...
(Date:8/31/2018)... ... August 30, 2018 , ... Small, wireless and networked describes ... down and getting connected, too. Draper’s latest system is tiny in size, but is ... A driving factor in the new implant design is the growing awareness that disease ...
Breaking Biology Technology:
Cached News: